Wegener's vasculitis, also known as Granulomatosis with Polyangiitis (GPA), is a rare autoimmune disease that primarily affects small and medium-sized blood vessels. The annual incidence is approximately 8-10 cases per million, with the prevalence estimated to be around 3 cases per 100,000 people. The disease accounts for a significant portion of vasculitic disorders, with a notable impact on kidney, lung, and upper respiratory tract function. There is a high unmet clinical need for better therapies to treat Wegener's Vasculitis, as current treatment options, such as corticosteroids and immunosuppressive agents, often lead to significant side effects. Further, the growing focus on targeted biologic therapies, personalized medicine, and advancements in immunotherapy are likely to support pipeline growth in the coming years, offering hope for improved management and outcomes for patients.
The Wegener Vasculitis Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into Wegener vasculitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Wegener vasculitis. The Wegener vasculitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Wegener vasculitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with Wegener vasculitis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Wegener vasculitis.
Wegener’s vasculitis, now known as granulomatosis with polyangiitis (GPA), is a rare but serious autoimmune disorder that causes inflammation of small- and medium-sized blood vessels. It primarily affects the kidneys, lungs, and upper respiratory tract. In this condition, the body's immune system mistakenly targets and attacks the blood vessels, leading to damage, decreased blood flow, and impaired organ function. While the exact cause is unknown, genetic predisposition and environmental triggers like infections are believed to play a role in its development.
Wegener vasculitis treatment generally involves a combination of medications to suppress the overactive immune system and reduce inflammation. High-dose corticosteroids, such as prednisone, are commonly used in the initial phase, often alongside cyclophosphamide or rituximab to target and reduce disease activity. Once the disease is under control, maintenance therapy may include methotrexate or azathioprine to prevent relapse. Frequent monitoring of organ function and side effects is crucial to ensure optimal outcomes and minimize complications.
This section of the report covers the analysis of Wegener Vasculitis drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total Wegener vasculitis clinical trials.
The drug molecule categories covered under the Wegener vasculitis pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Wegener vasculitis.
The EMR report for the Wegener Vasculitis report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Wegener vasculitis clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for Wegener vasculitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Wegener vasculitis drug candidates.
Sponsored by the NIH, the drug is currently under evaluation in a Phase 3 study. The objective of this study is to evaluate the impact of low-dose prednisone (5 mg/day) versus complete cessation (0 mg/day) on disease relapse rates in patients with remission from granulomatosis with polyangiitis (GPA). With 12 participants enrolled, the study is expected to be completed by December 2025.
The drug is under investigation in a Phase 2 study, sponsored by NS Pharma, Inc., that is designed to assess the safety and efficacy of NS-229 versus placebo in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA). The study will enroll approximately 45 participants and span 28 weeks. The main objective is to achieve clinical remission, defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 with a corticosteroid dose of ≤4 mg/day. The trial is expected to be completed by July 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Wegener Vasculitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Wegener vasculitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within Wegener vasculitis pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share